Cardiovascular and Renal Endpoints With Flozins - an Observational Prospective Study in CKD HFpEF Patients
Status: Recruiting
Location: See location...
Intervention Type: Other, Diagnostic test
Study Type: Observational
SUMMARY
The main aim of this study is to holistically assess the cardiovascular and renal outcomes in HFpEF CKD patients with and without SGLT2 inhibition, with focus on the endothelial disfunction, MACE and mortality using clinical evaluation, flow mediated dilatation, carotid-femoral pulse wave velocity, intima-media thickness, echocardiographic parameters, NMR metabolomics and a series of novel biomarkers.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• age\>18 years;
• ejection fraction \> 40;
• patients with CKD stage 3-4 (eGFR between 15-60 mL/min/1.73m2), with iSGLT2 recommendation, diabetic and non-diabetic;
• age, sex and CKD stage 3 and 4 matched patients without iSGLT2 administration.
Locations
Other Locations
Romania
Dr. C.I. Parhon Hospital in Iasi
RECRUITING
Iași
Time Frame
Start Date: 2025-01-08
Estimated Completion Date: 2027-12-31
Participants
Target number of participants: 200
Treatments
iSGLT2 therapy
CKD and HFpEF with iSGLT2 therapy
Control
CKD and HFpEF without iSGLT2 therapy
Related Therapeutic Areas
Sponsors
Collaborators: The Executive Agency for Higher Education, Research, Development and Innovation Funding, Dr. C.I. Parhon Hospital, Iasi
Leads: Grigore T. Popa University of Medicine and Pharmacy